Editing Curcumin (section)

==Medical research==
Although curcumin has been assessed in numerous laboratory and [[clinical research|clinical studies]], it has no medical uses established by well-designed clinical research.<ref name="lpi">{{cite web | url=http://lpi.oregonstate.edu/mic/dietary-factors/phytochemicals/curcumin | title=Curcumin | publisher=Linus Pauling Institute, Oregon State University, Corvallis | work=Micronutrient Information Center; Phytochemicals | date=2016 | access-date=June 18, 2016}}</ref> According to a 2017 review of more than 120 studies, curcumin has not been successful in any [[clinical trial]], leading the authors to conclude that "curcumin is an unstable, reactive, non-bioavailable compound and, therefore, a highly improbable lead".<ref name=nelson/> Curcumin exhibits numerous interference properties which may lead to misinterpretation of results.<ref name=nelson/><ref name=baker/><ref>{{cite news |last1=Lowe |first1=Derek |title=Curcumin Will Waste Your Time |url=https://www.science.org/content/blog-post/curcumin-waste-your-time |work=Science Blogs |date=12 January 2017 }}</ref>

The US government has supported US$150&nbsp;million in research into curcumin through the [[National Center for Complementary and Integrative Health]], and no support has been found for curcumin as a medical treatment.<ref name="nelson"/><ref name="Forbes-11917">{{cite news | vauthors = Lemonick S |title=Everybody Needs To Stop With This Turmeric Molecule |url= https://www.forbes.com/sites/samlemonick/2017/01/19/everybody-needs-to-quit-it-with-this-turmeric-molecule/#39ccce9079ff |access-date=May 27, 2018|work=[[Forbes (magazine)|Forbes]]|date=January 19, 2017}}</ref>

===Research fraud===
[[Bharat Aggarwal]], a former cancer researcher at the [[University of Texas MD Anderson Cancer Center]], had 29 papers retracted due to research fraud {{as of | July 2021 | lc=yes}}.<ref>{{cite web |title=The Retraction Watch Leaderboard |url=https://retractionwatch.com/the-retraction-watch-leaderboard/ |website=Retraction Watch |access-date=28 July 2021 |date=16 June 2015}}</ref><ref>{{cite web|url=http://www.chron.com/news/houston-texas/article/M-D-Anderson-professor-under-fraud-probe-3360037.php|title=M.D. Anderson professor under fraud probe| vauthors = Ackerman T |publisher=Houston Chronicle|date=February 29, 2012|access-date=March 8, 2016}}</ref><ref>{{cite news |title=Caught Our Notice: Researcher who once threatened to sue Retraction Watch now up to 19 retractions |url=https://retractionwatch.com/2018/04/10/caught-our-notice-researcher-who-once-threatened-to-sue-retraction-watch-now-up-to-19-retractions/#more-63985 |work=Retraction Watch |date=April 10, 2018}}</ref>  Aggarwal's research had focused on potential [[anti-cancer]] properties of herbs and spices, particularly curcumin, and according to a March 2016 article in the ''[[Houston Chronicle]]'', "attracted national media interest and laid the groundwork for ongoing clinical trials".<ref>{{cite news | vauthors = Ackerman T |title=M.D. Anderson scientist, accused of manipulating data, retires |url=https://www.houstonchronicle.com/news/houston-texas/houston/article/M-D-Anderson-scientist-accused-of-falsifying-6865704.php |work=Houston Chronicle |date=March 2, 2016}}</ref><ref name="SciAm">{{cite journal|title=Spice Healer| vauthors = Stix G |journal=Scientific American|date=February 2007|volume=296|issue=2|pages=66–69|doi=10.1038/scientificamerican0207-66|pmid=17367023|bibcode=2007SciAm.296b..66S}}</ref><ref>{{cite news|url=http://www.chron.com/news/houston-texas/article/In-cancer-fight-a-spice-brings-hope-to-the-table-1913487.php|title=In cancer fight, a spice brings hope to the table | vauthors = Ackerman T |work=Houston Chronicle|date=July 11, 2005|access-date=March 24, 2015}}</ref>  

Aggarwal cofounded a company in 2004 called Curry Pharmaceuticals based in [[Research Triangle Park]], [[North Carolina]], which planned to develop drugs based on synthetic analogs of curcumin.<ref name="SciAm"/><ref name="Singh1">{{cite journal | vauthors = Singh S | title = From exotic spice to modern drug? | journal = Cell | volume = 130 | issue = 5 | pages = 765–768 | date = September 2007 | pmid = 17803897 | doi = 10.1016/j.cell.2007.08.024 | s2cid = 16044143 | doi-access = free }}</ref> SignPath Pharma, a company seeking to develop [[Liposome|liposomal]] formulations of curcumin, licensed three patents by Aggarwal related to that approach from MD Anderson in 2013.<ref>{{cite news | vauthors = Baum S |title=Biotech startup raises $1M for lung cancer treatment using component of tumeric |url=https://medcitynews.com/2013/03/biotech-startup-raises-1m-for-lung-cancer-treatment-using-component-of-tumeric/ |work=Med City News |date=March 26, 2013}}</ref>